50=500 mg/kg. Symptoms of overdose includes suspected or overt abnormal bleeding (e.g., appearance of blood in stools or urine, hematuria, excessive menstrual bleeding, melena, petechiae, excessive bruising or persistent oozing from superficial injuries).
Coumarin derivative that acts as a long-acting oral anticoagulant.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
The presence of this polymorphism in CYP2C9 is associated with reduction in phenprocoumon metabolism.
The presence of this polymorphism in CYP2C9 is associated with reduction in phenprocoumon metabolism.
The presence of this polymorphism in VKORC1 is associated with reduction in phenprocoumon metabolism.
| Apixaban | Apixaban may increase the anticoagulant activities of Phenprocoumon. |
| Dabigatran etexilate | Dabigatran etexilate may increase the anticoagulant activities of Phenprocoumon. |
| Dasatinib | The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Phenprocoumon. |
| Deferasirox | The risk or severity of gastrointestinal bleeding can be increased when Phenprocoumon is combined with Deferasirox. |
| Ursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Hyodeoxycholic Acid. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with Phenprocoumon. |
| Ibrutinib | The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Phenprocoumon. |
| Obinutuzumab | The risk or severity of bleeding and hemorrhage can be increased when Phenprocoumon is combined with Obinutuzumab. |
| Rivaroxaban | Phenprocoumon may increase the anticoagulant activities of Rivaroxaban. |
| Sugammadex | The risk or severity of bleeding and hemorrhage can be increased when Phenprocoumon is combined with Sugammadex. |
| Tibolone | Tibolone may increase the anticoagulant activities of Phenprocoumon. |
| Tipranavir | The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Phenprocoumon. |
| Urokinase | Urokinase may increase the anticoagulant activities of Phenprocoumon. |
| Vitamin E | Vitamin E may increase the anticoagulant activities of Phenprocoumon. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Phenprocoumon. |
| Modafinil | The metabolism of Phenprocoumon can be increased when combined with Modafinil. |
| Armodafinil | The metabolism of Phenprocoumon can be increased when combined with Armodafinil. |
| Metreleptin | The metabolism of Phenprocoumon can be increased when combined with Metreleptin. |
| Mifepristone | The serum concentration of Phenprocoumon can be increased when it is combined with Mifepristone. |
| Gemcitabine | The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Gemcitabine. |
| Flunisolide | Flunisolide may increase the anticoagulant activities of Phenprocoumon. |
| Beclomethasone dipropionate | Beclomethasone dipropionate may increase the anticoagulant activities of Phenprocoumon. |
| Betamethasone | Betamethasone may increase the anticoagulant activities of Phenprocoumon. |
| Fluticasone propionate | Fluticasone propionate may increase the anticoagulant activities of Phenprocoumon. |
| Fluocinolone acetonide | Fluocinolone acetonide may increase the anticoagulant activities of Phenprocoumon. |
| Prednisone | Prednisone may increase the anticoagulant activities of Phenprocoumon. |
| Fludrocortisone | Fludrocortisone may increase the anticoagulant activities of Phenprocoumon. |
| Hydrocortisone | Hydrocortisone may increase the anticoagulant activities of Phenprocoumon. |
| Prednisolone | Prednisolone may increase the anticoagulant activities of Phenprocoumon. |
| Methylprednisolone | Methylprednisolone may increase the anticoagulant activities of Phenprocoumon. |
| Trilostane | Trilostane may increase the anticoagulant activities of Phenprocoumon. |
| Budesonide | Budesonide may increase the anticoagulant activities of Phenprocoumon. |
| Dexamethasone | Dexamethasone may increase the anticoagulant activities of Phenprocoumon. |
| Corticotropin | Corticotropin may increase the anticoagulant activities of Phenprocoumon. |
| Cortisone acetate | Cortisone acetate may increase the anticoagulant activities of Phenprocoumon. |
| Paramethasone | Paramethasone may increase the anticoagulant activities of Phenprocoumon. |
| Ciclesonide | Ciclesonide may increase the anticoagulant activities of Phenprocoumon. |
| Aldosterone | Aldosterone may increase the anticoagulant activities of Phenprocoumon. |
| Fluticasone furoate | Fluticasone furoate may increase the anticoagulant activities of Phenprocoumon. |
| Fluprednidene | Fluprednidene may increase the anticoagulant activities of Phenprocoumon. |
| Tixocortol | Tixocortol may increase the anticoagulant activities of Phenprocoumon. |
| Fluprednisolone | Fluprednisolone may increase the anticoagulant activities of Phenprocoumon. |
| Meprednisone | Meprednisone may increase the anticoagulant activities of Phenprocoumon. |
| Dexamethasone isonicotinate | Dexamethasone isonicotinate may increase the anticoagulant activities of Phenprocoumon. |
| Melengestrol | Melengestrol may increase the anticoagulant activities of Phenprocoumon. |
| Deflazacort | Deflazacort may increase the anticoagulant activities of Phenprocoumon. |
| Cortivazol | Cortivazol may increase the anticoagulant activities of Phenprocoumon. |
| Prednylidene | Prednylidene may increase the anticoagulant activities of Phenprocoumon. |
| Fluocortin | Fluocortin may increase the anticoagulant activities of Phenprocoumon. |
| Fluperolone | Fluperolone may increase the anticoagulant activities of Phenprocoumon. |
| Cloprednol | Cloprednol may increase the anticoagulant activities of Phenprocoumon. |
| Fluclorolone | Fluclorolone may increase the anticoagulant activities of Phenprocoumon. |
| Fluticasone | Fluticasone may increase the anticoagulant activities of Phenprocoumon. |
| Mometasone furoate | Mometasone furoate may increase the anticoagulant activities of Phenprocoumon. |
| Hydrocortisone acetate | Hydrocortisone acetate may increase the anticoagulant activities of Phenprocoumon. |
| Hydrocortisone cypionate | Hydrocortisone cypionate may increase the anticoagulant activities of Phenprocoumon. |
| Hydrocortisone succinate | Hydrocortisone succinate may increase the anticoagulant activities of Phenprocoumon. |
| Prednisolone phosphate | Prednisolone phosphate may increase the anticoagulant activities of Phenprocoumon. |
| Prednisolone hemisuccinate | Prednisolone hemisuccinate may increase the anticoagulant activities of Phenprocoumon. |
| Methylprednisolone hemisuccinate | Methylprednisolone hemisuccinate may increase the anticoagulant activities of Phenprocoumon. |
| Prednisone acetate | Prednisone acetate may increase the anticoagulant activities of Phenprocoumon. |
| Clocortolone acetate | Clocortolone acetate may increase the anticoagulant activities of Phenprocoumon. |
| Melengestrol acetate | Melengestrol acetate may increase the anticoagulant activities of Phenprocoumon. |
| Betamethasone phosphate | Betamethasone phosphate may increase the anticoagulant activities of Phenprocoumon. |
| Cortisone | Cortisone may increase the anticoagulant activities of Phenprocoumon. |
| Clobetasol propionate | Clobetasol propionate may increase the anticoagulant activities of Phenprocoumon. |
| Fluocinonide | Fluocinonide may increase the anticoagulant activities of Phenprocoumon. |
| Hydrocortisone butyrate | Hydrocortisone butyrate may increase the anticoagulant activities of Phenprocoumon. |
| Desoximetasone | Desoximetasone may increase the anticoagulant activities of Phenprocoumon. |
| Mometasone | Mometasone may increase the anticoagulant activities of Phenprocoumon. |
| Fluocortolone | Fluocortolone may increase the anticoagulant activities of Phenprocoumon. |
| Prednisolone acetate | Prednisolone acetate may increase the anticoagulant activities of Phenprocoumon. |
| Fluorometholone | Fluorometholone may increase the anticoagulant activities of Phenprocoumon. |
| Difluocortolone | Difluocortolone may increase the anticoagulant activities of Phenprocoumon. |
| Flumethasone | Flumethasone may increase the anticoagulant activities of Phenprocoumon. |
| Methylprednisolone aceponate | Methylprednisolone aceponate may increase the anticoagulant activities of Phenprocoumon. |
| Erlotinib | The serum concentration of Phenprocoumon can be increased when it is combined with Erlotinib. |
| Allopurinol | The risk or severity of bleeding can be increased when Allopurinol is combined with Phenprocoumon. |
| Azathioprine | The therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Azathioprine. |
| Chloral hydrate | The protein binding of Phenprocoumon can be decreased when combined with Chloral hydrate. |
| Methylphenidate | The metabolism of Phenprocoumon can be decreased when combined with Methylphenidate. |
| Disulfiram | Disulfiram may increase the anticoagulant activities of Phenprocoumon. |
| Etacrynic acid | The protein binding of Phenprocoumon can be decreased when combined with Etacrynic acid. |
| Ethotoin | The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Ethotoin. |
| Etoposide | The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Etoposide. |
| Exenatide | Exenatide can cause an increase in the absorption of Phenprocoumon resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Gefitinib | Gefitinib may increase the anticoagulant activities of Phenprocoumon. |
| Ginkgo biloba | Ginkgo biloba may increase the anticoagulant activities of Phenprocoumon. |